Overview Rapamycin Plus Bevacizumab in Advanced Cancers Status: Completed Trial end date: 2012-05-01 Target enrollment: Participant gender: Summary The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination. Phase: Phase 1 Details Lead Sponsor: University of ChicagoCollaborator: Genentech, Inc.Treatments: BevacizumabEverolimusSirolimus